Search

Your search keyword '"Cruz Hernandez, J.J."' showing total 47 results

Search Constraints

Start Over You searched for: Author "Cruz Hernandez, J.J." Remove constraint Author: "Cruz Hernandez, J.J."
47 results on '"Cruz Hernandez, J.J."'

Search Results

1. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

4. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

5. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer

6. 701P Genomic alteration relationships with toxicity to TPF induction chemotherapy in head and neck squamous cell carcinoma patients participating in a clinical trial

7. 692P Copy number alterations and response to radiotherapy + cisplatin vs radiotherapy + cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

8. 914P The landscape of somatic copy number alterations of head and neck squamous cell carcinoma across different anatomic sites

9. 913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer

12. 62P Influence of PAM50 on therapeutic decisions in patients with early-stage luminal breast cancer in a single centre

13. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

14. Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project

15. 1003P Expression by immunohistochemistry of p53 tumor suppressor protein as a predictive biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer

16. 455P Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)

18. The quality oncology practice initiative program: Experience in Spain

19. First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study

20. Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project

22. 242P Reclassification of variants of unknown significance in BRCA 1/2 genes for the improvement of care quality in oncological genetic council units

23. 215P Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification

24. 39P Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel

26. Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P)

27. How do Spanish medical oncologists manage breakthrough pain? A national study

28. 65P - Determination of anti-pancreatic islet cell antibodies for the prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immune checkpoint inhibitors

30. 1128P - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: Study PANTERA

36. 800P - Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P)

37. Incidence of Chemotherapy-Induced Nausea and Vomiting with Moderately Emetogenic Chemotherapy: Advice Study

39. Induction Chemotherapy (Ict) with Docetaxel/Cisplatin/5-Fluorouracil (T/P/F) Followed By Chemoradiotherapy with Cisplatin (Crtp) Vs Bioradiotherapy with Cetuximab (Rtcx) for Unresectable Locally Advanced Head & Neck Cancer (Ulahnc): Preliminary Results on Toxicity a Ttcc Group Trial

41. 1504P - Incidence of Chemotherapy-Induced Nausea and Vomiting with Moderately Emetogenic Chemotherapy: Advice Study

43. 1035P - Induction Chemotherapy (Ict) with Docetaxel/Cisplatin/5-Fluorouracil (T/P/F) Followed By Chemoradiotherapy with Cisplatin (Crtp) Vs Bioradiotherapy with Cetuximab (Rtcx) for Unresectable Locally Advanced Head & Neck Cancer (Ulahnc): Preliminary Results on Toxicity a Ttcc Group Trial

Catalog

Books, media, physical & digital resources